Must Read Articles

Engineering the Future of Cancer Care: How Next-Generation Antibody-Drug Conjugates (ADCs) Are Shaping Oncology and Beyond

Acute Myeloid Leukemia (AML) is a heterogeneous and highly aggressive hematologic malignancy characterized by a wide range of cytogenetic and molecular abnormalities that define distinct disease subgroups.

3rd Antibody-Drug Conjugate (ADC)  in Boston, MA, brought together a group of diverse yet deeply specialized experts who shared their knowledge, clinical insights, and technical experience with remarkable openness and clarity.

The Opportunity to go Beyond “chemo on a stick” ADCs

Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer therapeutics, offering significant advancements over traditional treatments. The global ADC market is projected to reach $11.29 billion in 2023, with an estimated compound annual growth rate (CAGR) of 9.2% between 2024 and 2030, reflecting substantial economic and scientific interest in this field

Finding Synergies in Combining ADCs with Multispecific Antibodies

The use of Artificial Intelligence (AI) is becoming increasingly prevalent in drug discovery and development and holds the potential to address the challenges in ADC development. AI requires substantial amounts of high-quality data to make reliable predictions of a novel ADC’s safety and efficacy. However, since this therapeutic area is still fairly new, there is limited data available to meet all the challenges of ADC development through AI. In such a scenario, enriching AI with knowledge (hybrid AI) is a very promising approach and provides high-accuracy predictions even in data-limited scenarios.

20-Hour Conjugation Bottlenecks – Confronting ADC Development Challenges with CDMOs

Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. However, payload...

The Roundup: July 2024